Cargando…
FoxO3a as a Positive Prognostic Marker and a Therapeutic Target in Tamoxifen-Resistant Breast Cancer
Background: Resistance to endocrine treatments is a major clinical challenge in the management of estrogen receptor positive breast cancers. Although multiple mechanisms leading to endocrine resistance have been proposed, the poor outcome of this subgroup of patients demands additional studies. Meth...
Autores principales: | Pellegrino, Michele, Rizza, Pietro, Donà, Ada, Nigro, Alessandra, Ricci, Elena, Fiorillo, Marco, Perrotta, Ida, Lanzino, Marilena, Giordano, Cinzia, Bonofiglio, Daniela, Bruno, Rosalinda, Sotgia, Federica, Lisanti, Michael P., Sisci, Diego, Morelli, Catia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966564/ https://www.ncbi.nlm.nih.gov/pubmed/31769419 http://dx.doi.org/10.3390/cancers11121858 |
Ejemplares similares
-
FoxO3a Inhibits Tamoxifen-Resistant Breast Cancer Progression by Inducing Integrin α5 Expression
por: Ricci, Elena, et al.
Publicado: (2022) -
From HDAC to Voltage-Gated Ion Channels: What’s Next? The Long Road of Antiepileptic Drugs Repositioning in Cancer
por: Pellegrino, Michele, et al.
Publicado: (2022) -
Mitochondrial “power” drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer
por: Fiorillo, Marco, et al.
Publicado: (2017) -
Androgens downregulate miR-21 expression in breast cancer cells underlining the protective role of androgen receptor
por: Casaburi, Ivan, et al.
Publicado: (2016) -
The Other Side of the Coin: May Androgens Have a Role in Breast Cancer Risk?
por: Chiodo, Chiara, et al.
Publicado: (2021)